IP Library Granted Patent US 11,098,338
Granted Patent B2
US 11,098,338 · App. 16/413,063 · Granted Aug 24, 2021

Recombinant polypeptide production methods

Inventors: Erhard Kopetzki (Penzberg, DE); Jens Niewoehner (Munich, DE); Peter Maier (Biberach an der Riss, DE)
Assignee: Hoffmann-La Roche Inc.
C12P21/005C07K5/1019C07K14/475C07K14/48C07K16/2863C07K16/2881C12P21/02C07K2317/14C07K2317/522C07K2317/524C07K2317/526C07K2317/53C07K2317/55C07K2317/56C07K2319/00C07K2319/50C07K2319/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,098,338
App. No.
16/413,063
Granted
Aug 24, 2021
Kind
B2
Abstract

Herein is reported a method for producing a fusion-polypeptide comprising the seeps of a) cultivating a mammalian cell comprising a nucleic acid encoding a variant fusion-polypeptide wherein the amino acid sequence of the fusion-polypeptide has been modified by replacing in a pro-fusion-polypeptide the endogenous protease cleavage site between the pro-peptide and the fusion-polypeptide with an exogenous (with respect to the origins of the parts of the fusion-polypeptide) or artificial protease cleavage site, and b) recovering the fusion-polypeptide or fusion-pro-polypeptide from the cell or the cultivation median and thereby producing the (recombinant) fusion-polypeptide.

Claims (11)

1. A method for producing a recombinant polypeptide, comprising the following steps:

cultivating a eukaryotic cell comprising a nucleic acid encoding a variant polypeptide wherein the polypeptide has been modified by introducing one or more artificial glycosylation sites located in a specific glycosylation tag that is fused either directly or via a linker to the polypeptide and consists of one of the following amino acid sequences: NGTEGPNFYVPFSNATGVV (SEQ ID NO: 10), NGTEGPNFYVPFSNATGVVR (SEQ ID NO: 16), AAANGTGGA (SEQ ID NO: 17), and NATGADNGTGAS (SEQ ID NO: 19), and

recovering the variant recombinant polypeptide from the cell or the cultivation medium.

2. The method according to claim 1 , wherein the producing steps comprise:

providing a nucleic acid encoding the polypeptide,

modifying the nucleic acid to encode a variant polypeptide wherein the amino acid sequence of the polypeptide has been modified to comprise one or more artificial glycosylation sites,

introducing the nucleic acid into a eukaryotic cell,

cultivating the eukaryotic cell, and

recovering the variant recombinant polypeptide from the cell or the cultivation medium and thereby producing the recombinant polypeptide.

3. The method according to claim 1 , wherein the eukaryotic cell is a mammalian cell.

4. The method according to claim 2 , wherein the eukaryotic cell is a mammalian cell.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2019
From: KOPETZKI, ERHARD; MAIER, PETER
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 051176/0856 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2019
From: ROCHE DIAGNOSTICS GMBH
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 051177/0031 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2019
From: NIEWOEHNER, JENS
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 051177/0348 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2019
From: F. HOFFMANN-LA ROCHE AG
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 051177/0702 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2019
From: F. HOFFMANN-LA ROCHE AG
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 051186/0294 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2019
From: ROCHE DIAGNOSTICS GMBH
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 051186/0334 →
Priority Claims (1)
EP 13198738 · Dec 20, 2013 · regional
Continuity (2)
Continuation 15106205
Related Publication 20190271021A1 · Sep 5, 2019
Cited By (3)
US 12,252,533 US 12,358,997 US 12,735,497